Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2
- 7 February 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 74 (5), 1241-1243
- https://doi.org/10.1093/jac/dkz026
Abstract
Objectives: Ceftazidime/avibactam resistance due to mutation in the omega loop of KPC-2 has been documented in vitro and in vivo. This study evaluated the mechanism of ceftazidime/avibactam resistance in a KPC-2-expressing Klebsiella pneumoniae isolated from a patient following ceftazidime/avibactam combination therapy with gentamicin for the treatment of ventilator-associated pneumonia. Methods: Ceftazidime/avibactam-susceptible and -resistant isolates of K. pneumoniae were evaluated by broth microdilution and WGS. The KPC-2 gene was cloned from the ceftazidime/avibactam-resistant isolate and evaluated for susceptibility to ceftazidime/avibactam, in an Escherichia coli background. Results: A single L169P mutation was identified in the KPC-2 gene between the ceftazidime/avibactam-resistant and -susceptible isolates. The novel KPC-2 allele, designated KPC-35, was shown to confer reduced susceptibility to ceftazidime/avibactam and increased susceptibility to carbapenems, as compared with KPC-2. Conclusions: A novel L169P mutation was identified in KPC-2 and was shown through cloning experiments to confer reduced susceptibility to ceftazidime/avibactam.This publication has 12 references indexed in Scilit:
- Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae InfectionsAntimicrobial Agents and Chemotherapy, 2018
- Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in bla KPC-2 -Harboring Klebsiella pneumoniae Sequence Type 307 IsolatesAntimicrobial Agents and Chemotherapy, 2018
- Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux ActivityAntimicrobial Agents and Chemotherapy, 2017
- Mutations in bla KPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-LactamasesAntimicrobial Agents and Chemotherapy, 2017
- Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying bla KPC Collected in U.S. Hospitals from 2012 to 2015Antimicrobial Agents and Chemotherapy, 2017
- Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae InfectionsAntimicrobial Agents and Chemotherapy, 2017
- Chromosomal Integration of the Klebsiella pneumoniae Carbapenemase Gene, bla KPC , in Klebsiella Species Is Elusive but Not RareAntimicrobial Agents and Chemotherapy, 2017
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.Clinical Infectious Diseases, 2016
- First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae IsolateAntimicrobial Agents and Chemotherapy, 2015
- Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loopJournal of Antimicrobial Chemotherapy, 2015